These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

595 related articles for article (PubMed ID: 28336368)

  • 1. Novel strategies in the oral delivery of antidiabetic peptide drugs - Insulin, GLP 1 and its analogs.
    Ismail R; Csóka I
    Eur J Pharm Biopharm; 2017 Jun; 115():257-267. PubMed ID: 28336368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New insights into nanomedicines for oral delivery of glucagon-like peptide-1 analogs.
    Pinto SFT; Santos HA; Sarmento BFCC
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2024; 16(2):e1952. PubMed ID: 38500351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral delivery of therapeutic protein/peptide for diabetes--future perspectives.
    Rekha MR; Sharma CP
    Int J Pharm; 2013 Jan; 440(1):48-62. PubMed ID: 22503954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin and GLP-1 analog combinations in type 2 diabetes mellitus: a critical review.
    Jendle J; Martin SA; Milicevic Z
    Expert Opin Investig Drugs; 2012 Oct; 21(10):1463-74. PubMed ID: 22799463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of advanced oral drug delivery technologies facilitating the protection and absorption of protein and peptide molecules.
    Choonara BF; Choonara YE; Kumar P; Bijukumar D; du Toit LC; Pillay V
    Biotechnol Adv; 2014 Nov; 32(7):1269-1282. PubMed ID: 25099657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delivery of Peptides Via the Oral Route: Diabetes Treatment by Peptide-Loaded Nanoparticles.
    Bouttefeux O; Beloqui A; Preat V
    Curr Pharm Des; 2016; 22(9):1161-76. PubMed ID: 26675223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery.
    Chae SY; Jin CH; Shin HJ; Youn YS; Lee S; Lee KC
    Bioconjug Chem; 2008 Jan; 19(1):334-41. PubMed ID: 18078308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transition from passive to active targeting of oral insulin nanomedicines: enhancement in bioavailability and glycemic control in diabetes.
    Kaklotar D; Agrawal P; Abdulla A; Singh RP; Mehata AK; Singh S; Mishra B; Pandey BL; Trigunayat A; Muthu MS
    Nanomedicine (Lond); 2016 Jun; 11(11):1465-86. PubMed ID: 27171572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multistage pH-responsive mucoadhesive nanocarriers prepared by aerosol flow reactor technology: A controlled dual protein-drug delivery system.
    Shrestha N; Shahbazi MA; Araújo F; Mäkilä E; Raula J; Kauppinen EI; Salonen J; Sarmento B; Hirvonen J; Santos HA
    Biomaterials; 2015 Nov; 68():9-20. PubMed ID: 26253804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide drug delivery strategies for the treatment of diabetes.
    Sadrzadeh N; Glembourtt MJ; Stevenson CL
    J Pharm Sci; 2007 Aug; 96(8):1925-54. PubMed ID: 17286287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral delivery of therapeutic peptides and proteins: Technology landscape of lipid-based nanocarriers.
    Haddadzadegan S; Dorkoosh F; Bernkop-Schnürch A
    Adv Drug Deliv Rev; 2022 Mar; 182():114097. PubMed ID: 34999121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies for the delivery of antidiabetic drugs via intranasal route.
    Dholakia J; Prabhakar B; Shende P
    Int J Pharm; 2021 Oct; 608():121068. PubMed ID: 34481011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral delivery of peptide drugs: barriers and developments.
    Hamman JH; Enslin GM; Kotzé AF
    BioDrugs; 2005; 19(3):165-77. PubMed ID: 15984901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A silica-based pH-sensitive nanomatrix system improves the oral absorption and efficacy of incretin hormone glucagon-like peptide-1.
    Qu W; Li Y; Hovgaard L; Li S; Dai W; Wang J; Zhang X; Zhang Q
    Int J Nanomedicine; 2012; 7():4983-94. PubMed ID: 23028226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral delivery of therapeutic proteins and peptides: a review on recent developments.
    Gupta S; Jain A; Chakraborty M; Sahni JK; Ali J; Dang S
    Drug Deliv; 2013 Aug; 20(6):237-46. PubMed ID: 23869787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel delivery technologies for protein and peptide therapeutics.
    Kumar TR; Soppimath K; Nachaegari SK
    Curr Pharm Biotechnol; 2006 Aug; 7(4):261-76. PubMed ID: 16918403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
    Trujillo JM; Nuffer W
    Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymer-based nanoparticles for oral insulin delivery: Revisited approaches.
    Fonte P; Araújo F; Silva C; Pereira C; Reis S; Santos HA; Sarmento B
    Biotechnol Adv; 2015 Nov; 33(6 Pt 3):1342-54. PubMed ID: 25728065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted nanoparticles towards increased L cell stimulation as a strategy to improve oral peptide delivery in incretin-based diabetes treatment.
    Xu Y; De Keersmaecker H; Braeckmans K; De Smedt S; Cani PD; Préat V; Beloqui A
    Biomaterials; 2020 Oct; 255():120209. PubMed ID: 32580098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in the oral delivery of insulin.
    Ramesan RM; Sharma CP
    Recent Pat Drug Deliv Formul; 2014; 8(2):155-9. PubMed ID: 24867419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.